HIF1A and neoplasm: One mechanism of tumor resistance to antiangiogenic therapy (e.g. bevacizumab) is upregulation of hypoxia-inducible factor 1α (HIF-1α), which mediates adaptive responses to hypoxic conditions [6, 23–30].